Institutional members access full text with Ovid®

Share this article on:

Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement

Comp, Philip C. MD, PhD; Spiro, Theodore E. MD; Friedman, Richard J. MD; Whitsett, Thomas L. MD; Johnson, Gerhard J. MD; Gardiner, Geoffrey A. Jr, MD; Landon, Glenn C. MD; Jové, Maurice MD, Enoxaparin Clinical Trial Group

Journal of Bone & Joint Surgery - American Volume: March 2001 - Volume 83 - Issue 3 - p 336

Background: Patients undergoing hip or knee joint replacement are at risk for venous thromboembolic complications for up to twelve weeks postoperatively. We evaluated the efficacy and safety of a prolonged post-hospital regimen of enoxaparin, a low-molecular-weight heparin, in this patient population.

Methods: Following elective total hip or knee replacement, 968 patients received subcutaneous enoxaparin (30 mg twice daily) for seven to ten days, and 873 were then randomized to receive three weeks of double-blind outpatient treatment with either enoxaparin (40 mg once daily) or a placebo. The primary efficacy end point was the prevalence of objectively confirmed venous thromboembolism or symptomatic pulmonary embolism during the double-blind phase of treatment.

Results: Of the 873 randomized patients, 435 underwent elective total hip replacement and 438 underwent elective total knee replacement. Enoxaparin was superior to the placebo in reducing the prevalence of venous thromboembolism in patients treated with hip replacement: 8.0% (eighteen) of the 224 patients treated with enoxaparin had venous thromboembolism compared with 23.2% (forty-nine) of the 211 patients treated with the placebo (p < 0.001; odds ratio, 3.62; 95% confidence interval, 2.00 to 6.55; relative risk reduction, 65.5%). Enoxaparin had no significant benefit in the patients treated with knee replacement: thirty-eight (17.5%) of the 217 patients treated with enoxaparin had venous thromboembolism compared with forty-six (20.8%) of the 221 patients treated with the placebo (p = 0.380; odds ratio, 1.24; 95% confidence interval, 0.76 to 2.02; relative risk reduction, 15.9%). Symptomatic pulmonary embolism developed in three patients, one with a hip replacement and two with a knee replacement; all had received the placebo. There was no significant difference in the prevalence of hemorrhagic episodes or other types of toxicity between the enoxaparin and placebo-treated groups.

Conclusions: Prolonging enoxaparin thromboprophylaxis following hip replacement for a total of four weeks provided therapeutic benefit, by reducing the prevalence of venous thromboembolism, without compromising safety. A similar benefit was not observed in patients treated with knee replacement.

Philip C. Comp, MD, PhD; Department of Medicine, The University Hospitals, 800 N.E. 13th Street, Room EB400, Oklahoma City, OK 73126. E-mail address:

Theodore E. Spiro, MD; Cardiovascular Therapeutic Area, European Operations Site, E2/309, Aventis Pharma, 20 Avenue Raymond Aron, 92160 Antony, France. E-mail address: Please address correspondence and requests for reprints to T.E. Spiro.

Richard J. Friedman, MD; Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425

Thomas L. Whitsett, MD; Department of Medicine, University of Oklahoma Health Sciences Center, Room 3120, 920 Stanton L. Young Boulevard, Oklahoma City, OK 73104

Gerhard J. Johnson, MD; Veterans Administration Medical Center, One Veterans Drive, Minneapolis, MN 55417. E-mail address:

Geoffrey A. Gardiner Jr., MD; Department of Radiology, Thomas Jefferson University Hospital, Suite 4200, Gibbons Building, 111 South 11th Street, Philadelphia, PA 19107

Glenn C. Landon, MD; Kelsey-Seybold Clinic, St. Luke’s Medical Tower, 6624 Fannin Street, Houston, TX 77030

Maurice Jové, MD; Atlanta Knee and Sports Medicine, 2801 North Decatur Road, Suite 200, Decatur, GA 30033

Copyright 2001 by The Journal of Bone and Joint Surgery, Incorporated
You currently do not have access to this article

To access this article: